<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Mon, 18 May 2026 09:02:16 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>InterVenn Biosciences adds Ford and Levine to board</title>
   <link>http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</link>
   <description>

&lt;p&gt;InterVenn Biosciences announced the appointment of Alec Ford and Mitch Levine to its board of directors. The South San Francisco-based life sciences company focuses on glycoproteomics for healthcare solutions.&lt;/p&gt;

&lt;p&gt;Ford brings over 30 years of experience in genomics, pharmaceutical and biotechnology industries. He currently serves as chief executive officer of Karius, a liquid biopsy company for infectious diseases. Ford previously held the chief operating officer position at Myriad Genetics, where he launched products and scaled business units in women's health, oncology, urology and prenatal screening. His career includes leadership roles at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer.&lt;/p&gt;

&lt;p&gt;Levine has extensive experience in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Biosciences adds Ford and Levine to board</title>
   <link>http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</link>
   <description>

&lt;p&gt;InterVenn Biosciences announced the appointment of Alec Ford and Mitch Levine to its board of directors. The South San Francisco-based life sciences company focuses on glycoproteomics for healthcare solutions.&lt;/p&gt;

&lt;p&gt;Ford brings over 30 years of experience in genomics, pharmaceutical and biotechnology industries. He currently serves as chief executive officer of Karius, a liquid biopsy company for infectious diseases. Ford previously held the chief operating officer position at Myriad Genetics, where he launched products and scaled business units in women's health, oncology, urology and prenatal screening. His career includes leadership roles at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer.&lt;/p&gt;

&lt;p&gt;Levine has extensive experience in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Biosciences adds Ford and Levine to board</title>
   <link>http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</link>
   <description>

&lt;p&gt;InterVenn Biosciences announced the appointment of Alec Ford and Mitch Levine to its board of directors. The South San Francisco-based life sciences company focuses on glycoproteomics for healthcare solutions.&lt;/p&gt;

&lt;p&gt;Ford brings over 30 years of experience in genomics, pharmaceutical and biotechnology industries. He currently serves as chief executive officer of Karius, a liquid biopsy company for infectious diseases. Ford previously held the chief operating officer position at Myriad Genetics, where he launched products and scaled business units in women's health, oncology, urology and prenatal screening. His career includes leadership roles at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer.&lt;/p&gt;

&lt;p&gt;Levine has extensive experience in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Biosciences adds Ford and Levine to board</title>
   <link>http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</link>
   <description>

&lt;p&gt;InterVenn Biosciences announced the appointment of Alec Ford and Mitch Levine to its board of directors. The South San Francisco-based life sciences company focuses on glycoproteomics for healthcare solutions.&lt;/p&gt;

&lt;p&gt;Ford brings over 30 years of experience in genomics, pharmaceutical and biotechnology industries. He currently serves as chief executive officer of Karius, a liquid biopsy company for infectious diseases. Ford previously held the chief operating officer position at Myriad Genetics, where he launched products and scaled business units in women's health, oncology, urology and prenatal screening. His career includes leadership roles at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer.&lt;/p&gt;

&lt;p&gt;Levine has extensive experience in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/InterVenn+Biosciences+adds+Ford+and+Levine+to+board/26511195.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:16 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors</title>
   <link>http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ca.sousco&quot; idsrc=&quot;xmltag.org&quot; &gt;SOUTH SAN FRANCISCO, Calif.&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 18, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;&lt;u&gt;&lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4690170-1&amp;amp;h=2444645601&amp;amp;u=https%3A%2F%2Fintervenn.com%2F&amp;amp;a=InterVenn+Biosciences&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;InterVenn Biosciences&lt;/a&gt;&lt;/u&gt;&lt;/b&gt;, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of &lt;person&gt;Alec Ford&lt;/person&gt; and &lt;person&gt;Mitch Levine&lt;/person&gt; to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.&lt;/p&gt;
&lt;p&gt;&quot;We are excited to welcome Alec and Mitch to InterVenn's Board of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/InterVenn+Appoints+Industry+Leaders+Alec+Ford+and+Mitch+Levine+to+Board+of+Directors/26511191.html</guid>
   <pubDate>Mon, 18 May 2026 09:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.20422478</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21111274</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">OCX</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
  <item>
   <title>The Biology Came First.</title>
   <link>http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</link>
   <description>
&lt;p&gt;
&lt;i&gt;Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&amp;apos;s work today.&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
&lt;b&gt;MindWalk Holdings Corp. (NASDAQ: HYFT) &lt;/b&gt;today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case,</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html</guid>
   <pubDate>Mon, 18 May 2026 08:34:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">0QW0</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.02264286</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.03302840</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.15343852</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ARGX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CGEM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IDXX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IPA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00017340</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00222364</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00338863</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.02598349</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.03259153</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.04870500</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.29492292</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.49467714</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">XNCR</category>
   	  </item>
 </channel>
</rss>
